Patients
infection, Cytopenia, cytopenia, Hb ≤
RECURRENCE, DISEASE, CYTOPENIA, INFECTION, CYTOPENIA, ONCOLOGY, HYPOCELLULAR
The study was conducted from September 2017 to August 2020 and included 21 patients treated with PLX-R18 in 8 study sites in the US and Israel. Adult patients ( ≥ 18 years), at least 3 months after allo- or auto-HCT with sustained cytopenia, defined as platelet (PLT) count ≤ 50,000/µL, and/or Hb ≤ 8 g/dL, and/or ANC ≤ 1000/µL, were eligible for the study. Cytopenia was confirmed by at least 2 consecutive blood counts and a hypocellular BM. Complete and stable donor chimerism in at least 3 consecutive tests prior to treatment was required. Patients had to have no other observed causes of cytopenia (e.g., active infection, disease recurrence, grade 3–4 acute GvHD or severe chronic GvHD) at the time of study entry. Finally, patients needed to have a life expectancy of over 6 months and a score of 0–2 on the Eastern Cooperative Oncology Group (ECOG) performance scale. Complete eligibility criteria are listed in the supplementary information- List S